Lille, France and San Diego, CA – Lunginnov, a France based provider of novel reagents for the study of vascular remodelling and endothelial dysfunctions, has entered into a distribution agreement with Abcore, a US based provider of custom polyclonal antibodies and representative and distributer for small European biotech companies in North America.
Together with Abcore, Lunginnov will now be able to expand access and distribution of its novel research product line of monoclonal antibodies, recombinant proteins, kits and immunoassays to the North American markets. The Lunginnov product line focuses on targets central to the study of vascular remodelling and endothelial dysfunctions, which intersects a diverse range of research areas including cancer, angiogenesis, inflammation, sepsis and obesity.
“We are excited to enter into an agreement with Abcore to distribute our product line in North America. With an excellent reputation as a provider of custom reagents and as a distributer for European companies we believe Abcore will help us meet, and expand, the international demand for our products in the region”, comments Omar Daoudi, International atoledo.com Sales & Marketing Manager, Lunginnov s.a.s.
“Lunginnov is an established provider of high quality products for both research and diagnostic purposes within Europe”, said David Barraclough, VP, Sales & Marketing, Abcore “and through our distribution agreement with Lunginnov we can now offer an even greater range of reliable, tried and tested products in to North America”
About Abcore: Abcore is a biotech company that provides custom polyclonal antibody services worldwide; and represents small European biotech companies in North America. Antibody services are performed in Southern California at USDA licensed facilities. Headquartered in San Diego, CA, Abcore is at the centre of life science discovery and innovation.
About Lunginnov: Lunginnov is a privately owned life sciences company, creating value by discovering novel biomarkers to assess endothelial dysfunctions and by promoting their development and regulatory qualification. The company found its name from the first ELISA kit that detects respiratory failure in sepsis available on the European market since the beginning of 2013. The company also offers services such as monoclonal antibody production, specific immunoassay development and endothelial dysfunction studies. For its innovative approach, the company has been awarded and supported since its inception in 2009 by several regional and national partners as: Eurasanté, Région